Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
P19 - Immunotherapy (Phase II/III Trials) - Previously Treated NSCLC
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P19.01 - RATIONALE-303 Phase 3 Tislelizumab vs Docetaxel in Previously Treated Advanced NSCLC: China Subgroup Analysis
00:00 - 00:00 | Presenter: Yun Fan
- Abstract
Loading... -
+
P19.02 - Sintilimab Plus Docetaxel in Previously Treated Advanced NSCLC, Updates on Progression-Free and Overall Survival
00:00 - 00:00 | Presenter: Zhehai Wang
- Abstract
Loading...
-
+
P21 - Liquid Biopsy and Other Non-invasive Diagnostic Modalities - IO
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
-
+
P21.01 - Selected ctDNA Panel Gene Sequencing for Neoantigen Discovery and Survival Prediction in Patients With Stage IV Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Feng Ming Spring Kong
- Abstract
Loading... -
+
P21.02 - Real-World Concordance Between Tumor Mutational Burden From Blood and Tissue in Lung Cancer and Other Cancers
00:00 - 00:00 | Presenter: Jewel Park
- Abstract
Loading...
-
+
P22 - Liquid Biopsy and Other Non-invasive Diagnostic Modalities - Monitoring/Prognosis
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
-
+
P22.01 - Personalized ctDNA Assay for MRD Detection and Treatment Response Monitoring in a Patient With Metastatic Lung Cancer
00:00 - 00:00 | Presenter: Georges Azzi
- Abstract
Loading... -
+
P22.02 - Combined Use of CYFRA 21-1, CA125 and CRP Predicts Survival of Metastatic NSCLC Patients With Stable Disease
00:00 - 00:00 | Presenter: Namrata S Patil
- Abstract
Loading... -
+
P22.03 - Role of Circulating Tumor Cell Subpopulations in Operable Non-Small Cell Lung Cancer Diagnosis and Prognosis
00:00 - 00:00 | Presenter: Emanuela Fina
- Abstract
Loading... -
+
P22.04 - Prospective Validation of an Eight Gene mRNA Signature in Plasma for the Diagnosis of Early Stage Lung Cancer
00:00 - 00:00 | Presenter: Ana María Giménez Capitán
- Abstract
Loading... -
+
P22.05 - Dynamic Monitoring of Blood Samples by PEAC Technology for Early-Stage Lung Cancer Patients After Surgery
00:00 - 00:00 | Presenter: Yue Pu
- Abstract
Loading... -
+
P22.06 - Prognostic Value of Circulating Tumor Cells in Patients With Small Cell Lung Cancer Receiving Front-Line Treatment
00:00 - 00:00 | Presenter: Haohua Zhu
- Abstract
Loading...
-
+
P23 - Liquid Biopsy and Other Non-invasive Diagnostic Modalities - Screening and Early Detection
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
-
+
P23.01 - Integration of Metabolomics and Transcriptomics to Reveal Metabolic Disorder in Early Lung Cancer for Non-invasive diagnosis
00:00 - 00:00 | Presenter: xinrong Jiang
- Abstract
Loading... -
+
P23.02 - Digital Multiplexed circRNA Analysis From Plasma-Derived Extracellular Vesicles of Lung Cancer Patients
00:00 - 00:00 | Presenter: Carlos Pedraz-Valdunciel
- Abstract
Loading... -
+
P23.03 - Novel Serum Extracellular Vesicles Based miR-153-3p Biomarker Combined to a Prediction Model for Determining Early-Stage Lung Cancer
00:00 - 00:00 | Presenter: Yuxia Deng
- Abstract
Loading... -
+
P23.04 - Serum Biomarkers Enhance Prognostic Value of Computed Tomography (CT) in Patients With Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Rebecca Gerber
- Abstract
Loading... -
+
P23.05 - Chromosome 3p22.1 and 10q22.3 Amplification in Different Subtypes of Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Qi Wang
- Abstract
Loading...
-
+
P24 - Liquid Biopsy and Other Non-invasive Diagnostic Modalities - Targeted Therapy
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Liquid Biopsy and Other Non-invasive Diagnostic Modalities
-
+
P24.01 - Turnaround Time and Variant Prevalence of a Blood-based KRAS Test in Patients With NSCLC
00:00 - 00:00 | Presenter: Edgardo S Santos
- Abstract
Loading... -
+
P24.02 - Unique Efficacy of Ensartinib on Different ALK Fusion Subtypes Evaluated by Plasma ctDNA
00:00 - 00:00 | Presenter: Tao Wang
- Abstract
Loading... -
+
P24.03 - Dynamic Circulating Tumor DNA Interim Results From The ALKternate Clinical Trial
00:00 - 00:00 | Presenter: Malinda Itchins
- Abstract
Loading... -
+
P24.04 - Concordance of Tissue and Cell-Free DNA-Based Next-Generation Sequencing in Patients With Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Misha Tran
- Abstract
Loading... -
+
P24.05 - Using Liquid Biopsies to Guide First-Line Therapy Decisions in Patients With Metastatic Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Luis E. Raez
- Abstract
Loading... -
+
P24.06 - Resistance Mechanisms Exploring of NSCLC With Central Nervous System Metastases Using Liquid Biopsy of Cerebrospinal Fluid: A Real-World Study
00:00 - 00:00 | Presenter: Guilan Dong
- Abstract
Loading... -
+
P24.07 - An Ultra-Sensitive Protocol for ctDNA Mutation Detection With Application in Lung Cancers
00:00 - 00:00 | Presenter: Yue Pu
- Abstract
Loading... -
+
P24.08 - Lung Cancer Diagnosis in Absence of Adequate Tissue Molecular Analysis in Metastatic Disease by NGS Analysis of Plasma cfDNA
00:00 - 00:00 | Presenter: Christi M.J. Steendam
- Abstract
Loading... -
+
P24.09 - Association Between Circulating EGFR Mutant Tumor DNA and Tumor Lesion Glycolysis in Patients with EGFR Mutated Metastatic Lung Adenocarcinoma
00:00 - 00:00 | Presenter: Zhasmina Mihaylova
- Abstract
Loading... -
+
P24.10 - Identification of ctDNA using MassARRAY Technology in a Cross-Sectional Study of NSCLC Patients
00:00 - 00:00 | Presenter: Ken O'Byrne
- Abstract
Loading... -
+
P24.11 - Cell-Free Tumor DNA (ctDNA) Utility in Detection and Monitoring EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Jason Agulnik
- Abstract
Loading... -
+
P24.12 - Biomarker Testing for Advanced Lung Cancer by Next-Generation Sequencing in Elderly Patients.
00:00 - 00:00 | Presenter: luis Roberto basbus
- Abstract
Loading... -
+
P24.13 - Circulating Tumor Cells Predict Prognosis Following First-Generation EGFR-TKI Treatment in EGFR- and TP53-Mutant Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: wen gao
- Abstract
Loading... -
+
P24.14 - Validation of Companion Diagnostics for the Identification of Patients with EGFR Exon20ins NSCLC for Amivantamab Therapy
00:00 - 00:00 | Presenter: Timothy Jatkoe
- Abstract
Loading...
-
+
P25 - Locally Advanced Non-Small Cell Lung Cancer - Concurrent Chemotherapy/ Radiotherapy
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Locally Advanced Non-Small Cell Lung Cancer
-
+
P25.01 - Efficacy of Weekly Paclitaxel-Bevacizumab Combination in Advanced NSCLC: AVATAX, A Retrospective Multicentric Study
00:00 - 00:00 | Presenter: Geoffroy Bilger
- Abstract
Loading... -
+
P25.02 - Concurrent Chemoradiotherapy With Cisplatin + S-1 for Locally Advanced Non-Small Cell Lung Cancer: IPD Meta-Analysis
00:00 - 00:00 | Presenter: Yuri Taniguchi
- Abstract
Loading...
-
+
P26 - Locally Advanced Non-Small Cell Lung Cancer - EGFR Targeted Therapy
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Locally Advanced Non-Small Cell Lung Cancer
-
+
P26.01 - Detecting Oligo-Metastatic/Progressive Disease in Advanced EGFR-Mutant NSCLC: PET/CT and Conventional Imaging Methods
00:00 - 00:00 | Presenter: Dayu Xu
- Abstract
Loading... -
+
P26.02 - A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results
00:00 - 00:00 | Presenter: Collin M. Blakely
- Abstract
Loading...
-
+
P27 - Locally Advanced Non-Small Cell Lung Cancer - Other & Local Treatment Toxicity
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Locally Advanced Non-Small Cell Lung Cancer
-
+
P27.01 - Patterns of Care and Outcomes in Clinical T3N0M0 Non-Small Cell Lung Cancer Without Invasion of Other Structures
00:00 - 00:00 | Presenter: Matthew Willis Parsons
- Abstract
Loading... -
+
P27.02 - Associating Cardiac Plaque Accumulation With Cardiac Toxicity and Overall Survival In Locally Advanced Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Andreas Rimner
- Abstract
Loading... -
+
P27.03 - Increase in Overall Survival for Locally Advanced NSCLC Patients From 2010 to 2018 - A Registry Based Study in Denmark
00:00 - 00:00 | Presenter: Peter Meldgaard
- Abstract
Loading... -
+
P27.04 - Clinical Outcomes for Patients With Stage III NSCLC and STK11 or KEAP1 Genetic Alterations
00:00 - 00:00 | Presenter: Sean Maximillian Taasan
- Abstract
Loading... -
+
P27.05 - High Body Mass Index (BMI) Is Associated With Better Outcomes in Mexican Patients With Advanced Non–Small Cell Lung Cancer (NSCLC)
00:00 - 00:00 | Presenter: Saul Campos-Gomez
- Abstract
Loading... -
+
P27.06 - Multiscale NSCLC Tumor Growth Knowledge-Based Model Reproduces Tumor-Non-Progression under Gefitinib
00:00 - 00:00 | Presenter: Adèle L'Hostis
- Abstract
Loading... -
+
P27.07 - Pancoast Tumour Presenting as Lower Limb Weakness; Would You Recognise It?
00:00 - 00:00 | Presenter: Gaurav Jha
- Abstract
Loading... -
+
P27.08 - Accurate Positioning Technology for Lung Cancer Radiotherapy
00:00 - 00:00 | Presenter: Yaping Xu
- Abstract
Loading...
-
+
P28 - Locally Advanced Non-Small Cell Lung Cancer - Post PACIFIC Use of Durvalumab
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Locally Advanced Non-Small Cell Lung Cancer
-
+
P28.01 - Real-World Experience (RWE) of Consolidation Durvalumab After Concurrent Chemoradiotherapy (CCRT) In Stage III NSCLC
00:00 - 00:00 | Presenter: Yiqing Huang
- Abstract
Loading... -
+
P28.02 - Beyond PACIFIC: Outcomes and Toxicity According to Durvalumab Dosing Schedule Every 2 versus 4 Weeks
00:00 - 00:00 | Presenter: Marie-Hélène Denault
- Abstract
Loading... -
+
P28.03 - Durvalumab Adjuvant to Chemoradiation for Patients With Locally Advanced Non-Small Cell Lung Cancer: Real World Experience
00:00 - 00:00 | Presenter: Vilde Drageset Haakensen
- Abstract
Loading... -
+
P28.04 - Pneumonitis With Durvalumab Following Concurrent Chemoradiotherapy
00:00 - 00:00 | Presenter: Wissam Hanayneh
- Abstract
Loading...
-
+
P29 - Locally Advanced Non-Small Cell Lung Cancer - Radiation Planning and Delivery
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Locally Advanced Non-Small Cell Lung Cancer
-
+
P29.01 - Deformable vs. Rigid Registration in Evaluating Composite Doses to Central Organs at Risk in Thoracic Reirradiation
00:00 - 00:00 | Presenter: David Cooper
- Abstract
Loading... -
+
P29.02 - Early GLS Changes Detection After Chemoradiation in Locally Advanced NSCLC
00:00 - 00:00 | Presenter: Sara Ramella
- Abstract
Loading... -
+
P29.03 - Thoracic Organs at Risk (OARs) Contouring Variations and Consensus in Radiation Therapy for Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Feng Ming Spring Kong
- Abstract
Loading... -
+
P29.04 - Treatment Plan Parameters and Toxicity Following Chemoradiotherapy and High-Dose Radiotherapy in Stage III Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Merle I. Ronden
- Abstract
Loading... -
+
P29.05 - Gross Tumor Volume Contouring Variations in Radiation Therapy of Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Feng Ming Spring Kong
- Abstract
Loading... -
+
P29.06 - Both Endostar and Amifostine Reduced All the Incidence of Pneumonitis Above Grade 2 in Chemoradiotherapy With Locally Advanced NSCLC
00:00 - 00:00 | Presenter: Kuifei Chen
- Abstract
Loading... -
+
P29.07 - A Phase Ib Trial of Neoadjuvant Low-Dose Radiation Therapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC
00:00 - 00:00 | Presenter: Juan Li
- Abstract
Loading... -
+
P29.08 - Evaluation of the Prognostic Marker of PD-L1 Expression After Combined Radiochemotherapy in Patients With NSCLC Stage III
00:00 - 00:00 | Presenter: Jan Wagner
- Abstract
Loading...
first
prev
